Company intelligence / Profile preview

Pernix Therapeutics

Morristown, New Jersey, United Statesen.wikipedia.org ↗

Ownership: Private
Employees: ~128
Development stage: Commercial

Overview

Pernix Therapeutics was a specialty pharmaceutical company that marketed branded and generic pharmaceutical products. The company filed for Chapter 11 bankruptcy on February 18, 2019, and went out of business on June 24, 2019[1][2].

Therapeutic areas: PsychiatryNeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

Treximet

Commercial

Indications: Pain

3 more assets in the full pipeline.

Request access →

Partnerships

GSK (for Treximet)

Beyond the preview

Go deeper on Pernix Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pernix Therapeutics.

Explore the full profile